These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785 [TBL] [Abstract][Full Text] [Related]
4. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. van Iersel LB; de Leede EM; Vahrmeijer AL; Tijl FG; den Hartigh J; Kuppen PJ; Hartgrink HH; Gelderblom H; Nortier JW; Tollenaar RA; van de Velde CJ Eur J Surg Oncol; 2014 Nov; 40(11):1557-63. PubMed ID: 25125340 [TBL] [Abstract][Full Text] [Related]
5. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715 [TBL] [Abstract][Full Text] [Related]
6. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. Libutti SK; Barlett DL; Fraker DL; Alexander HR J Am Coll Surg; 2000 Nov; 191(5):519-30. PubMed ID: 11085732 [TBL] [Abstract][Full Text] [Related]
7. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Rothbarth J; Tollenaar RA; Schellens JH; Nortier JW; Kool LJ; Kuppen PJ; Mulder GJ; van de Velde CJ Eur J Cancer; 2004 Aug; 40(12):1812-24. PubMed ID: 15288282 [TBL] [Abstract][Full Text] [Related]
8. Isolated hepatic perfusion: a regional therapy for liver cancer. Yang ZW; Xu GL Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):12-6. PubMed ID: 14969830 [TBL] [Abstract][Full Text] [Related]
9. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Alexander HR; Butler CC Cancer J; 2010; 16(2):132-41. PubMed ID: 20404610 [TBL] [Abstract][Full Text] [Related]
10. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Zeh HJ; Brown CK; Holtzman MP; Egorin MJ; Holleran JL; Potter DM; Bartlett DL Ann Surg Oncol; 2009 Feb; 16(2):385-94. PubMed ID: 19034580 [TBL] [Abstract][Full Text] [Related]
11. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. van Etten B; Brunstein F; van IJken MG; Marinelli AW; Verhoef C; van der Sijp JR; Guetens G; de Boeck G; de Bruijn EA; de Wilt JH; Eggermont AM Ann Surg Oncol; 2004 Jun; 11(6):598-605. PubMed ID: 15172933 [TBL] [Abstract][Full Text] [Related]
12. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Nakamoto T; Inagawa H; Takagi K; Soma G Anticancer Res; 2000; 20(6A):4087-96. PubMed ID: 11131677 [TBL] [Abstract][Full Text] [Related]
13. Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors. Ku Y; Tominaga M; Iwasaki T; Fukumoto T; Kuroda Y Int J Clin Oncol; 2002 Apr; 7(2):82-90. PubMed ID: 12018114 [TBL] [Abstract][Full Text] [Related]
14. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. van Etten B; de Wilt JH; Brunstein F; Eggermont AM; Verhoef C Eur J Surg Oncol; 2009 May; 35(5):539-45. PubMed ID: 18760560 [TBL] [Abstract][Full Text] [Related]
15. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207 [TBL] [Abstract][Full Text] [Related]
16. Outcome analysis of a decade-long experience of isolated hepatic perfusion for unresectable liver metastases at a single institution. Magge D; Choudry HA; Zeh HJ; Cunningham DE; Steel J; Holtzman MP; Jones HL; Pingpank JF; Bartlett DL; Zureikat AH Ann Surg; 2014 May; 259(5):953-9. PubMed ID: 24169176 [TBL] [Abstract][Full Text] [Related]
17. Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies. Jones A; Alexander HR Surg Oncol Clin N Am; 2008 Oct; 17(4):857-76, x. PubMed ID: 18722923 [TBL] [Abstract][Full Text] [Related]
19. Curative and palliative aspects of regional chemotherapy in combination with surgery. Müller H; Hilger R Support Care Cancer; 2003 Jan; 11(1):1-10. PubMed ID: 12527948 [TBL] [Abstract][Full Text] [Related]